Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)


Phase 1/2 Results N/A

Summary of Purpose

The investigators propose to determine the engraftment and transplant related morbidity and mortality after a non-myeloablative allogeneic hematopoietic stem cell transplant protocol using immune- suppressive agents and low-dose total body irradiation (TBI) without standard chemotherapy in patients with aggressive sickle cell disease who are not candidates for or experienced complications from hydroxyurea...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 19 April 2017.

11 Nov 2011 23 Nov 2011 1 May 2018 1 May 2018 1 Apr 2017 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Masking: Open Label
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Single Group Assignment